Valuation: Affimed N.V.

Market Cap 18.84M 20.79M 17.43M 15.72M 29.63M 1.96B 30.68M 209M 83.01M 1.05B 78.03M 76.37M 3.32B P/E 2022
-1.92x
P/E 2023 -0.8x
Enterprise Value -336K -371K -311K -281K -529K -34.99M -548K -3.74M -1.48M -18.69M -1.39M -1.36M -59.33M EV / Sales 2022
0.03x
EV / Sales 2023 4.69x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
Current month+9,900.00%
1 month-66.67%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.04
1 year 0
Extreme 1.0E-6
0.05
3 years 0
Extreme 1.0E-6
8.95
5 years 0
Extreme 1.0E-6
73.5
10 years 0
Extreme 1.0E-6
117.4
Manager TitleAgeSince
Chief Executive Officer 42 2024-09-02
Director of Finance/CFO 61 2023-12-30
Chief Executive Officer 65 2024-01-14
Director TitleAgeSince
Chairman 75 2006-12-31
Director/Board Member 71 2016-01-20
Director/Board Member 60 2020-08-03
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%-100.00% 1.64K
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.55%+0.04%+33.05%+152.77% 41B
Weighted average by Cap. -0.83%+0.20%+36.60%+156.10%

Financials

2022 2023
Net sales 42.87M 47.31M 39.65M 35.78M 67.42M 4.46B 69.8M 476M 189M 2.38B 178M 174M 7.56B 13.91M 15.35M 12.87M 11.61M 21.88M 1.45B 22.65M 155M 61.3M 773M 57.62M 56.4M 2.45B
Net income -86M -94.91M -79.55M -71.77M -135M -8.95B -140M -956M -379M -4.78B -356M -349M -15.17B -106M -117M -97.99M -88.41M -167M -11.02B -172M -1.18B -467M -5.89B -439M -429M -18.69B
Net Debt -172M -190M -159M -144M -271M -17.91B -280M -1.91B -758M -9.57B -713M -698M -30.36B -19.18M -21.16M -17.74M -16M -30.16M -2B -31.22M -213M -84.49M -1.07B -79.42M -77.73M -3.38B
Projected Income Statement - Annual - Affimed N.V.
Logo Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Employees
76
Date Price Change Volume
26-11-10 US$0.000100 0.00% 880
26-11-06 US$0.000100 -50.00% 200
  1. Stock Market
  2. Stocks
  3. AFMDQ Stock